RS Sequencer with Hugh Martin, PacBio

Podcast Sponsor: Singulex- Watch our cardiovascular monitoring programs explained on YouTube


Hugh Martin, former CEO, Pacific Biosciences Bio and Contact Info

Listen (1:45) Key events for 2011

Listen (9:05) RS Sequencer and its advantages

Listen (9:04) Disadvantages

Listen (:54) What happened to the stock?

Listen (2:30) Mike Hunkapiller joins team

Listen (6:16) What makes a good CEO?

Listen (2:17) How do you keep good people?

Listen (5:54) Fighting cancer personally

Listen (2:42) Clinical sequencing

Listen (3:50) Company direction

Listen (3:27) CSO Eric Schadt moves to NY

As part of our series, Sequencing and Genomic Medicine, I interviewed Hugh Martin of PacBio at the end of 2011. Personally, Hugh made headlines in 09 when he went public with his diagnosis of multiple myeloma. Previously, he served as CEO of ONI Systems—a high-speed optical telecommunications company he founded in 1998 and took public in 2000 and sold to Ciena in 2002 for $1 billion. Mr Martin led PacBio through an IPO and the commercial launch of their much anticipated RS Sequencer. On Jan 6 of 2012 it was announced that Mike Hunkapiller would step in as the new CEO. We hope to bring Mike to the program soon.